Medical Communications
FDA grants accelerated approval to Pfizer’s Elrexfio
August 15, 2023 Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval
FDA grants orphan drug designation to Genprex’s Reqorsa
August 15, 2023 Medical Communications FDA, ODD, Oncology, Reqorsa
FDA approves Talvey for the treatment of heavily pretreated multiple myeloma
August 11, 2023 Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma
Regeneron shares two-year PULSAR trial results for wAMD
August 11, 2023 Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD
Astellas announces FDA approval for Izervay for GA treatment
August 7, 2023 Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy
FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment
August 3, 2023 Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho
FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma
August 3, 2023 Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma
FDA approves a second OTC naloxone nasal spray
July 31, 2023 Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids
Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial
July 25, 2023 Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial
ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention
July 24, 2023 Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir
WHO releases Medical Product Alert for contaminated cough syrup
July 20, 2023 Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization
Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone
July 19, 2023 Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera
FDA approves first OTC daily oral contraceptive pill
July 14, 2023 Medical Communications Contraception, FDA, OTC, Opill, contraceptive pill
EMA accepts Astellas’ MAA for Zolbetuximab
July 14, 2023 Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab
ADC Therapeutics puts clinical trial enrollment on hold following patient deaths
July 12, 2023 Medical Communications ADC Therapeutics, DLBCL, Oncology, clinical trial
Latest content
